Autoinflammatory & rare systemic diseases
Renal outcomes and survival in amyloidosis associated with familial Mediterranean fever: A longitudinal study
Authors' conclusion
FMF-amyloidosis generally has poor long-term prognosis, significantly influenced by the amyloid burden at diagnosis.
Study context
- Population
- Patients with Familial Mediterranean fever (FMF)-associated amyloidosis treated between 2000 and 2022
- Participants
- 61 patients
- Exposure
- Estimated glomerular filtration rate (eGFR) <67 vs ≥67 mL/min/1.73 m² at amyloidosis diagnosis; IL-1 blockers
- Outcome
- Rate of end-stage renal disease or death during the study period
Methodological detailslongitudinal, Kaplan-Meier analysis, maximally selected rank statistics
- Longitudinal
- Kaplan-Meier analysis
- Maximally selected rank statistics
Main finding
As reported in the abstract
End-stage renal disease or death · mean of 10.8 ± 9.6 years from diagnosis of amyloid nephropathy
Attained the primary outcome
82%
Observational data: associations, not effects.
Further findings
10-year kidney or overall survival by eGFR cutoff at amyloidosis diagnosis
10-year kidney or overall survival by eGFR cutoff at amyloidosis diagnosis
- eGFR cutoff <67 mL/min/1.73 m² significantly associated with shorter time to endpoint
Outcome determinants at amyloidosis diagnosis
- Lower eGFR and increased concomitant medication usage were significant outcome determinants
IL-1 blocker treatment (13 patients)
- No impact on outcomes (Kaplan-Meier)
- 13
Original publication
Renal outcomes and survival in amyloidosis associated with familial Mediterranean fever: A longitudinal study. Semin Arthritis Rheum. Published 30 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →